151391-75-2

Basic information

• Product Name: Benzoic acid, 2-hydroxy-5-[(E)-[(2-hydroxyphenyl)methylene]amino]-
• Synonyms: 2-Hydroxy-5-{[1-(2-hydroxy-phenyl)-meth-(E)-ylidene]-amino}-benzoic acid;5-{[(1E)-(2-hydroxyphenyl)methylene]amino}-2-hydroxybenzoic acid
• CAS NO: 151391-75-2
• Molecular Formula: C14H11NO4
• Molecular Weight: 257.24100
• Mol File: 151391-75-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 2-hydroxy-5-[(E)-[(2-hydroxyphenyl)methylene]amino]-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 2-hydroxy-5-[(E)-[(2-hydroxyphenyl)methylene]amino]-(151391-75-2)
• EPA Substance Registry System: Benzoic acid, 2-hydroxy-5-[(E)-[(2-hydroxyphenyl)methylene]amino]-(151391-75-2)

Safety Data

• Hazardous Substances Data: 151391-75-2(Hazardous Substances Data)

Upstream product

• 89-95-2 2-methyl-benzyl alcohol 
• 89-57-6 5-Aminosalicylic Acid 
• 90-02-8 salicylaldehyde 

Downstream Products

• 873784-76-0 (HOOCC₆H₃OHNCHC₆H₄O)2Pd 
• 873784-80-6 (HOOCC₆H₃OHNCHC₆H₄O)2Zn 
• 873784-78-2 (HOOCC₆H₃OHNCHC₆H₄O)2Cu 

Relevant articles and documents

Design and synthesis of heterobimetallic topoisomerase I and II inhibitor complexes: In vitro DNA binding, interaction with 5′-GMP and 5′-TMP and cleavage studies

New potential cancer chemotherapeutic complexes Cu-Sn2/Zn-Sn2 3 and 4 were designed and prepared as topoisomerases inhibitors; their in vitro DNA binding studies were carried out which reveal strong electrostatic binding via phosphat

Effect of 5-substituted benzylideneaminosalicylic acid on carrageenan-induced ulcerative colitis.

Mesalazine, a drug of choice in the management of ulcerative colitis, was chemically modified as 5-(E)-substituted benzylideneaminosalicylic acid by condensing 5-aminosalicylic acid with selected aryl aldehydes with an intention to improve its pharmacological profile. The tests were performed to study their anti-inflammatory effect on carrageenan-induced ulcerative colitis in albino rats. The histopathological findings, serum transaminase level and lipid peroxide content in the intestine and liver were taken as indices of pharmacological activity. The azomethine derivative formed from salicylaldehyde (5-ASASB3) was found to have maximum activity and it reversed the disease symptoms in experimental animals The azomethine derivative markedly reduces the ulcerative colitis when compared with parent molecule, mesalazine.